Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kristine A. Kuhn, Liudmila Kulik, Beren Tomooka, Kristin J. Braschler, William P. Arend, William H. Robinson, V. Michael Holers
Published in Volume 116, Issue 4
J Clin Invest. 2006; 116(4):961–973 doi:10.1172/JCI25422
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 6
Antibodies against citrullinated fibrinogen can overcome the protective effect of tolerance to citrullinated antigens.

Mice were tolerized with LXP, challenged twice with CII in CFA, and then administered either 2 mg of equal amounts of 1042 and 1618 or 2 mg of the control HB5 antibody on days 22 and 28 after the initial challenge with CII in CFA. (A) Arthritis scores were measured between days 21 and 35, and (B) histologic evaluation was performed on paws collected on day 35. Data are shown as group averages α SEM. Statistical significance was determined by 1-way ANOVA. *P < 0.05; **P < 0.01 in comparison with the LXP plus HB5 control group. Mice tolerized with LKP, challenged with CII in CFA, and given monoclonal antibodies 1042/1618 or HB5 served as additional controls. No difference was detected between these groups and the LXP plus 1042/1618 group (data not sho).